Clinical Trials Sponsored by Endeavor Biomedicines, Inc.

Total 21 results

Endeavor Biomedicines, Inc.

Completed

A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

Canada, Malaysia, Australia, Mexico, Korea, Republic of
Endeavor Biomedicines, Inc.

Active, not recruiting

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Solid Tumors With PTCH1 Loss-of-function Mutations

United States
Endeavor Biomedicines, Inc.

Completed

A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects

Idiopathic Pulmonary Fibrosis

Australia
GAIA BioMedicine Inc.

Recruiting

Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC

NSCLC | Cell Therapy

Japan
Eisai Inc.
H3 Biomedicine Inc.

Withdrawn

A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

Urinary Bladder Neoplasms

United States
Eisai Inc.
H3 Biomedicine Inc.

Completed

A Study to Evaluate the Food-Effect of H3B-6527

Healthy Participants

United States
H3 Biomedicine Inc.
Eisai Inc.

Completed

Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma

Liver Neoplasms | Hepatocellular Carcinoma | Advanced Hepatocellular Carcinoma | Liver Cancer | Hepatic Cancer | Hepatic Carcinoma

France, United States, Belgium, Spain, Taiwan, Korea, Republic of, Russian Federation, Canada, Italy, Singapore, United Kingdom
Eisai Inc.
H3 Biomedicine Inc.

Terminated

Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101

Lymphoma | Advanced Solid Tumors

United States, Spain, France, Korea, Republic of, United Kingdom
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Active, not recruiting

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera

Australia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Completed

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Canada
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Completed

A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment

Healthy Volunteers | Hepatic Impairment

United States
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Completed

A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects

Healthy Volunteers

United States
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Available

Individual Patient Compassionate Use of Fedratinib

Myelofibrosis

United States
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Completed

Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects

Healthy Volunteers

United States
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Completed

Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin

Healthy Volunteers

United States
Fundacion para la Innovacion en Biomedicina (FIBMED)
Biosense Webster, Inc.

Active, not recruiting

Hybrid Characterization of Driver Sites During Atrial Fibrillation and Sinus Rhythm (Hybrid-AFMAP)

Persistent Atrial Fibrillation

Spain
Noah Merin
Teva Branded Pharmaceutical Products R&D, Inc.; Miltenyi Biomedicine GmbH

Active, not recruiting

Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Lymphoma | Multiple Myeloma | Hodgkin Lymphoma | Chronic Lymphocytic Leukemia | CLL

United States
Ilaria Colombo
Ente Ospedaliero Cantonale, Bellinzona; Institute for Research in Biomedicine

Completed

A Study on the Immune-response to COVID-19 Vaccination in Cancer Patients - the IOSI-COVID-19-001 Study

Cancer | Covid19

Switzerland
Ricardo Pereira Mestre
Oncology Institute of Southern Switzerland; Institute of Oncology Research; Institute...

Terminated

Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1

COVID-19 Infection

Switzerland
Maria Betânia Almeida Dias Ferreira
Central Hospital, Nancy, France; Instituto de Ciências Biomédicas Abel Salazar and other collaborators

Completed

Cardiovascular Profiles in Rheumatoid Arthritis (RA-HF)

Cardiovascular Diseases | Heart Failure | Rheumatoid Arthritis | Cardiovascular Risk Factor | Myocardium; Injury
Fundación Pública Andaluza para la Investigación...
Instituto de Salud Carlos III; Spanish Biomedical Research Centre in Diabetes...

Completed

Incidence of Type 2 Diabetes in the di@Bet.es Study

Diabetes Mellitus, Type 2

Spain

Clinical Trials Sponsored by Endeavor Biomedicines, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations